SCHEMBL8965208

SCHEMBL8965208

Cc1ccc(C=CC(=O)c2ccc(O)cc2)cc1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 3/20 0.69
MAPT P10636 6/20 0.69
RAB9A P51151 5/20 0.69
MAOB P27338 3/20 0.69
MAOA P21397 2/20 0.69
POLB P06746 1/20 0.69
NPC1 O15118 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
ESR1 P03372 1/20 0.59
ESR2 Q92731 1/20 0.59
CXCL12 P48061 1/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
ALDH1A1 P00352 2/20 0.59
P4HB P07237 1/20 0.59
CALM1 P0DP23 1/20 0.59
XDH P47989 1/20 0.59
LMNA P02545 1/20 0.59
GAA P10253 1/20 0.59
CASP3 P42574 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8965212 1.00 F3 (0.69) F3MAPTRAB9AMAOBMAOA
SCHEMBL30384171 1.00 F3 (0.69) F3MAPTRAB9AMAOBMAOA
SCHEMBL8977062 0.90 F3 (0.69) F3MAPTRAB9AMAOBMAOA
SCHEMBL8977060 0.90 F3 (0.69) F3MAPTRAB9AMAOBMAOA
SCHEMBL31233310 0.89 BACE1 (0.68) F3MAPTRAB9AMAOBMAOA
SCHEMBL19193673 0.88 MAPT (0.58) MAPTRAB9AMAOBMAOAPOLB
SCHEMBL11937144 0.86 MAPT (0.63) F3MAPTRAB9AMAOBMAOA
SCHEMBL13297182 0.86 MAPT (0.64) F3MAPTRAB9AMAOBMAOA
SCHEMBL8964936 0.86 MAPT (0.56) F3MAPTRAB9AMAOBMAOA
SCHEMBL13359041 0.85 MAPT (0.66) F3MAPTRAB9AMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-5525457-A Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1996-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B F3 5/4885MAPT 3297/4885RAB9A 480/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 F3 11/4885MAPT 3512/4885RAB9A 1327/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 F3 11/4885MAPT 3512/4885RAB9A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.